CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Myriad Genetics And Epic Join Forces To Expand Access To Genetic Testing For More Patients

Myriad Genetics And Epic Join Forces...

How AIin Biotech and PharmaceuticalImpacts Drug Discovery

How AIin Biotech and...

The Value of New Antibiotics in the Fight Against AMR

The Value of New Antibiotics in the...

Improving Minimal Residual Disease Detection Using NGS

Improving Minimal Residual Disease...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Myriad Genetics And Epic Join Forces To Expand Access To Genetic Testing For More Patients

Myriad Genetics And Epic Join Forces...

How AIin Biotech and PharmaceuticalImpacts Drug Discovery

How AIin Biotech and...

The Value of New Antibiotics in the Fight Against AMR

The Value of New Antibiotics in the...

Improving Minimal Residual Disease Detection Using NGS

Improving Minimal Residual Disease...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Masco Group now a major stakeholder of Swedish company, KeyPlants AB

Life Sciences Review Life Sciences Review | Friday, November 26, 2021
Tweet

Summary: Masco Group buys a majority stake in KeyPlants AB, bolstering the company's flexible facilities and engineering technology solutions for life sciences customers.


Fremont, CA ;The healthcare industry has been hit by the digital disruption wave. While the scope and speed of change this will bring to the industry are still being debated, there is no doubt that transformation is already underway. Several disruptive forces in the healthcare sector have been pushing this barrier and changing the way patients are catered to. The Masco Group has acquired a major share in KeyPlants AB, a Swedish company. Masco's position in engineering technology for bio sciences will be strengthened as a result of this move.


By combining Masco Group's leadership in clean utilities and process technologies with KeyPlants' knowledge and innovative energy in prefabricated, modular facility solutions, this cooperation will boost Masco Group. It will provide a global customer base of biopharmaceutical manufacturers and CDMOs focused on biologics, pharma, and advanced therapy medicinal products (ATMPs), such as cell and gene therapies, with stronger value propositions for global supply chain challenges such as flexibility, reliability, and fast-track manufacturing timelines.


KeyPlants is a leading international industry partner for process-integrated modular prefabricated facility solutions that are both standardized and customizable. The company, based in Stockholm, has a completely integrated supply chain with more than 45 years of project engineering, manufacture, and delivery experience, and has delivered over 3,500 high-specification modules to at least 30 nations.


“We are extremely happy to partner with KeyPlants, as it will expand our capabilities, service and product offerings, and evolve our manufacturing capacity,” says Luca Borella, CEO of Masco Group. “We look forward to working with them to further accelerate the global adoption of their innovative fast-track facility solutions, which are an essential aspect in the life science industry.The companies share similar values, notably the commitment to teamwork, sustainability and customer care. Innovation is also an important synergetic element.”


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/masco-group-now-a-major-stakeholder-of-swedish-company-keyplants-ab-nwid-642.html